肿瘤坏死因子相关凋亡诱导配体启动子区-716位点单核苷酸多态性与前列腺癌危险因素的研究

目的：研究肿瘤坏死因子相关凋亡诱导配体（TRAIL）启动子区-716A／G位点单核苷酸多态性（SNP）与影响前列腺癌危险因素的关系。方法：应用聚合酶链反应-连接酶特异检测技术（PCR-LDR）分析186例前列腺癌患者TRAIL基因-716位点的多态性，比较不同基因型与前列腺癌患者诊断时的前列腺癌特异性抗原（PSA）、Gleason评分和TNM临床分期的关系。结果：TRAIL-716G（AG＋GG）等位基因与PSA、Gleason评分和TNM临床分期均具有显著的相关性（adjustedOR=0．04，0．07，0．08；95％CI：0．01～0．14，0．02～0．29，0．03～0．21）。结论：TRAIL-A716G（AG＋GG）等位基因可能与前列腺癌预后有关，携带TRAIL-716G（AG＋GG）等位基因的前列腺癌患者可能预后较好。

Association of Polymorphism in Promoter of TRAIL-716 Genotypes and Risk Factors of Prostate Cancer

Objective： To investigate the potential association between the polymorphism in promoter of TRAIL-716 genotypes and risk factors （PSA, Gleason score and TNM clinical stage） of prostate cancer. Methods： The polymorphism of TRAIL-716 sites was analyzed by polymerase chain reaction-ligase detection reaction （PCR-LDR） technique using genomic DNA isolated from peripheral blood. The association between the risk factors of prostate cancer and different genotypes was evaluated. Results：The TRAIL-716G variant allele （AG＋GG） was associated with lower PSA value of prostate cancer （adjusted OR = 0.04; 95%CI = 0.01-0. 14）. It was also noted that the TRAIL-716G variant allele was associated with lower Gleason score and earlier TNM clinical stage of prostate cancer patients （adjusted OR = 0. 07, 0.08; 95% CI = 0.02-0. 29, 0. 03-0. 21, respectively）. Conclusions： The results demonstrated that the TRAIL-716 A to G variant influenced the PSA value, Gleason score and TNM clinical stage of prostate cancer. The TRAIL-716G variant might have a protective effect in the prognosis of prostate cancer.